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Abstract
Background: Cardiac troponin is the preferred biomarker 
of myocardial injury. High-sensitivity troponin assays 
allow measurement of very low levels of troponin with 
excellent precision. After the introduction of a high-sen-
sitivity troponin I assay the laboratory began to receive 
enquiries from clinicians about clinically discordant ele-
vated troponin I results. This led to a systematic investiga-
tion and characterisation of the cause.
Methods: Routine clinical samples were measured by 
the Architect High Sensitive Troponin-I (hsTnI) and the 
VITROS Troponin I ES assays (VitrosTnI). Results that were 
elevated according to the Architect but not the VITROS 
assay (Group 1) or results elevated by both assays but dis-
proportionately higher on the Architect (Group 2) were 
re-analysed for hsTnI after re-centrifugation, multiple 
dilutions, incubation with heterophilic blocking reagents, 
polyethylene glycol (PEG) precipitation, and Protein 
A/G/L treatment. Sephacryl S-300 HR gel filtration chro-
matography (GFC) was performed on selected specimens.
Results: A high molecular weight complex containing 
immunoreactive troponin I and immunoglobulin (macro-
troponin I) was identified in 5% of patients with elevated 
hsTnI. Patients with both macrotroponin and myocardial 
injury had higher and longer elevation of hsTnI compared 
with VitrosTnI with peaks of both macrotroponin and free 
troponin I-C complex on GFC.
Conclusions: Circulating macrotroponin I (macroTnI) 
causes elevated hsTnI results with the Architect High 
Sensitive Troponin-I assay with the potential to be clini-
cally misleading. The assay involved in this investigation 
may not be the only assay affected by macrotroponin. It 
is important for laboratories and clinicians to be aware of 
and develop processes to identify and manage specimens 
with elevated results due to macrotroponin.
Keywords: false-positive troponin; high-sensitivity assay; 
macrotroponin; macrotroponin I.
Introduction
Cardiac troponin is the preferred biomarker of myocardial 
injury and is central to the universal definition of myocar-
dial infarction (MI), relying on a rise and/or fall of troponin 
with at least one value above the 99th percentile in patients 
with characteristic symptoms, imaging or electrocardio-
graphic evidence of myocardial ischaemia [1]. The evolution 
of cardiac troponin I (cTnI) assays has led to the availability 
of methods which measure cTnI with excellent precision at 
the low concentrations found in healthy individuals. These 
high-sensitivity assays have been defined as having a CV 
of   ≤  10% at the 99th percentile of a cardiac-healthy popu-
lation and the ability to measure cardiac troponin above 
the limit of detection in at least 50% of this population [2]. 
The hope is that high-sensitivity troponin assays will lead 
to earlier diagnosis of acute coronary syndrome and, with 
their enhanced sensitivity and sex- specific cutoffs, may 
improve patient outcomes, especially in women. However, 
there is insufficient evidence yet to conclude whether these 
outcomes have been achieved [3–6].
Since the 1960s, circulating macroanalytes have 
been known to cause misleadingly elevated clinical 
laboratory results. The majority of macroanalytes are 
believed to consist of an analyte bound to analyte-specific 
 autoantibodies resulting in high molecular weight com-
plexes which are cleared more slowly from the circulation 
than the free analyte resulting in persistently elevated 
levels. Cases have been described for cardiac troponins 
[7, 8], prolactin, thyroid-stimulating hormone and numer-
ous routinely measured enzymes [9–15].
In general, autoantibodies which form macroanalyte 
complexes are not believed to be disease-causing although 
cases associated with autoimmune disorders have been 
described [16, 17] and reports suggesting an association 
between the presence of autoantibodies against cTnI and 
cardiomyopathy have been published [18–20]. Based on 
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current evidence, the main problem caused by a circulat-
ing macroanalyte is that it leads to multiple, possibly inva-
sive, investigations in search of a cause.
Circulating troponin autoantibodies are not rare, 
having been identified in 2%–20% of individuals, with or 
without cardiac disease, in various studies [20–24]. They 
may be directed towards cTnI [19, 22] or cardiac troponin 
T [20, 21].
Historically, autoantibodies to cTnI have caused neg-
ative interference in some cTnI immunoassays [24, 25]. 
Investigation of the epitope specificity of cTnI autoan-
tibodies has shown that the cTnI midfragment (amino 
acids 30–100) is the commonest target of these antibod-
ies [26, 27]. The desire to standardise or harmonize cTnI 
measurement led to a recommendation that cTnI assays 
use antibodies specific to epitopes in the midfragment as 
this central portion is the most stable, being least likely to 
be affected by posttranslational modifications to the mol-
ecule, proteolytic degradation and circulating troponin 
complexes [2, 28]. However, it has been suggested that this 
recommendation be re-evaluated in the light of evidence 
about troponin autoantibody predilection for the midter-
minal region [27].
While cTnI autoantibodies are typically associated 
with false-negative cTnI immunoassay results, two cases 
of macrotroponin causing elevated cTnI have been pub-
lished [7, 8]. In these cases the presence of macrotroponin 
was proven by a panel of investigations. False-positive 
cTnI immunoassay results may be caused by factors other 
than macrotroponin, including interfering antibodies, 
fibrin microclots, carryover, random error and haemolysis 
[29–32].
When the clinical features of a patient and the cTnI 
results are discordant, investigation for preanalytical or 
analytical causes of a false-positive or negative result is 
mandatory. Laboratory investigations include analysis by 
an alternate method, re-centrifugation and re-analysis to 
exclude random error, treatment with heterophile anti-
body blocking agents, multiple dilutions of the specimen 
to identify non-linearity and polyethylene glycol (PEG) 
precipitation to remove a high molecular weight interfer-
ent [7, 8, 33]. Further evidence that an interferent is an 
immunoglobulin may be obtained by precipitation with 
an immunoglobulin-binding protein such as Protein A or 
G [7, 8]. Evidence for interference by a factor with a differ-
ent molecular weight to cTnI can be obtained by gel filtra-
tion chromatography (GFC) [7, 26].
A few months after the introduction of the Architect 
high sensitive troponin-I (hsTnI) assay into our labora-
tory we noticed an increase in enquiries regarding possi-
ble false-positive troponin I results. Initial investigations 
revealed that the false-positive results were likely to be 
due to a high molecular weight complex in the patients’ 
plasma. We considered replacing the assay but our clini-
cians requested that we continue providing the high-sen-
sitivity assay as it was so effective in a 2-h rapid rule-out 
protocol for MI. The relatively high frequency of this issue 
led us to set up a process to pre-emptively identify samples 
with spuriously high hsTnI results early in the diagnostic 
pathway and to characterise the nature of the interfer-
ence. We also performed a panel of tests on the first 50 
affected samples in order to determine the most reliable 
and efficient way of processing potentially false-positive 
results so that clinicians could be notified of the discrep-
ancy in the shortest period of time.
Materials and methods
Routine lithium heparin plasma samples were analysed for cTnI by 
the Architect High Sensitive Troponin-I assay on the Architect i4000 
SR analyser (Abbott Diagnostics, Brisbane, Australia) and the VIT-
ROS Troponin I ES (VitrosTnI) assay on a VITROS 5600 analyser 
(Ortho Clinical Diagnostics, Sydney, Australia). The VitrosTnI assay 
was selected because of its availability with the laboratory’s existing 
instrumentation. Passing-Bablok analysis of 6700 in-house concord-
ant samples demonstrated a 25% positive bias of the VITROS assay 
(y = 1.25x+2.6 where y = VitrosTnI, x = hsTnI). VitrosTnI results were 
not routinely reported to clinicians, but used as a screening tool by 
the laboratory to identify possible spuriously raised hsTnI results. 
Samples were analysed in real-time, with turnaround times  < 60 min 
for both results and no refrigeration or freezing. Both methods were 
verified and kept in control through standard laboratory procedures.
For hsTnI Australia adopted the manufacturer’s 99th percentile 
reference limit of 16 ng/L for females and the overall reference limit 
of 26 ng/L for males. In this laboratory the total imprecision is 4% at 
both 16 ng/L and 26 ng/L. The limit of quantification is 2 ng/L. For the 
VitrosTnI assay the manufacturer’s 99th percentile upper reference 
limit is 34 ng/L (CV = 7%) and limit of quantification is 12 ng/L.
All hsTnI results above the sex-specific 99th percentile cut-offs 
were scrutinised for concordance between the two assays. Sample 
volume permitting, the first 50 specimens with elevated hsTnI but 
VitrosTnI results below the cut-off (Group 1) or with hsTnI at least 2x 
VitrosTnI (Group 2) were subjected to the following procedures and 
reanalysed by the hsTnI assay: re-centrifugation of an aliquot (7 min 
at 1800 g) followed by re-analysis (n = 50), incubation in Heterophilic 
Blocking Tubes (Scantibodies Laboratory, Santee, CA, USA) accord-
ing to the manufacturer’s instructions (n = 44), dilution 1/2, 1/5 and 
1/10 with Architect Multi-Assay Manual Diluent (Abbott Diagnostics) 
(n = 45), PEG precipitation (n = 50), treatment with Protein A/G/L-
Sepharose (BioVision, Milpitas, CA, USA) (n = 38), and in selected 
cases GFC (n = 21). Samples were only refrigerated or frozen prior to 
GFC or Protein A/G/L treatment.
Plasma specimens from patients with concordant hsTnI and 
VitrosTnI elevations were used as controls for the PEG precipitation, 
Protein A/G/L binding and GFC. Numerical results below the hsTnI 
limit of quantification of 2 ng/L were used to calculate the post-PEG 
hsTnI recovery.
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Sample volume permitting discordant specimens (n = 37) were 
also analysed with the previous generation Architect Troponin I 
assay, the Architect STAT Troponin-I assay (manufacturer’s 99th 
percentile 28 ng/L). Passing-Bablok analysis of a 300 specimen 
in-house comparison: y = 0.96x+1.90 where y = hsTnI and x = STAT 
 Troponin-I, R2 = 0.997. Reagents were supplied without cost by 
Abbott Diagnostics.
PEG precipitation was performed using a 25% solution of 
8000 mol wt PEG [34] in phosphate buffered saline (PBS) (both from 
Sigma-Aldrich, Castle Hill, Australia). Two hundred microlitres of 
PEG solution was mixed with 200 μL patient or control plasma by 
vortexing. After incubation at room temperature for 10 min and cen-
trifugation (5  min at 16,000 g) the supernatant was analysed and 
results multiplied by 2 to adjust for dilution by the PEG solution. The 
recovery of hsTnI was then calculated as the percentage of hsTnI 
in the supernatant divided by the original result from the patients’ 
plasma. Patient and control recoveries were compared. Recovery 
below that of controls indicated the presence of high molecular 
weight interference.
Protein A/G/L-Sepharose treatment was performed in 2  mL 
screw cap microtubes (Quality Scientific Plastics, San Diego, CA, 
USA) containing 500 μL Protein A/G/L-Sepharose slurry as provided 
by the manufacturer. The Protein A/G/L-Sepharose was prepared by 
washing and centrifuging (10 min at 16,000 g) twice with 1 mL bind-
ing buffer (0.05 M sodium borate, 0.15 M sodium chloride, pH 8.0). 
The supernatant was removed, 300 μL patient or control plasma 
added and the contents mixed at ambient temperature on an orbital 
shaker (250 rpm) for 1 h. The plasma supernatant was removed from 
the tube after centrifugation (10 min at 16,000 g) and analysed. The 
recovery of hsTnI was then calculated as the percentage of hsTnI 
in the supernatant divided by the original result from the patients’ 
plasma. Patient and control recoveries were compared. Recovery 
below that of controls indicated the presence of high molecular 
weight interference. Results were not adjusted to account for dilution 
due to residual binding buffer because, although as much superna-
tant as possible was removed, it was not possible to accurately esti-
mate the residual buffer volume. Any dilutional effect would have 
been comparable for both control and discordant samples. The Pro-
tein A/G/L-Sepharose was regenerated by washing and centrifuging 
twice with elution buffer (0.1 M citric acid, pH 2.75) and once with dis-
tiled water. The microtubes of Protein A/G/L-Sepharose were stored 
refrigerated in 20% ethanol/H2O until re-use.
Samples were selected for GFC either at random, to clarify 
equivocal PEG precipitation results or to investigate Group 2 samples 
or serial samples with a rise in hsTnI. Initially a 9/300 GL column 
(GE Healthcare, Australia) containing Sephacryl S-300 HR (Sigma-
Aldrich; separation range 10–1500 kDa globular proteins) was used 
at a bed volume of 14 mL with a mobile phase of PBS. When the 9/300 
column required replacement due to loss a 10/400 GL column (GE 
Healthcare Life Sciences, Australia) was purchased as the 9/300 col-
umn size had been superseded. A bed volume of 24 mL was employed 
with the new column in order to improve resolution to investigate 
an impression that two different molecular weight species of macro-
troponin had been detected. Depending on the hsTnI concentration, 
200–500 μL of patient or control plasma was applied to the column. 
An initial effluent volume of 5.3 mL was discarded then 330 μL frac-
tions collected. As well as hsTnI, fractions were analysed for prolactin 
(Architect, Abbott Diagnostics, Brisbane, Australia) IgG, IgA and IgM 
(Immage, Beckman Coulter, Sydney, Australia) to act as molecular 
markers (23 kDa, 150 kDa, 340 kDa and 900 kDa, respectively). In one 
experiment plasma from a patient with elevated hsTnI post-MI was 
mixed (equal volumes incubated at room temperature for 10  min) 
with plasma from a patient with macroTnI and subjected to GFC.
To exclude the unlikely possibility that our findings were matrix-
related, PEG studies were replicated on EDTA plasma and serum from 
three patients with discordant results.
Wilcoxon-Mann-Whitney tests were applied to compare differ-
ences in PEG and protein A/G/L recovery with controls due to non-
normally distributed data and small sample sizes of some groups. 
Statistics were performed using Analyse-it® (Version 2.26, Analyse-it 
Software Ltd, Leeds, UK).
Mater Health Services Human Research Ethics Committee 
approval was granted to publish the findings.
Results
Incidence
Over a 4-month period (from 01/06/2015 to 30/09/2015) 
3897 individuals had hsTnI and VitrosTnI measured in 
parallel by the laboratory. Of these, 1074 (582 males) had 
hsTnI results above the sex-specific 99th percentile cut-
offs. Fifty-one individuals (5%) had elevated hsTnI results 
(range 16–683 ng/L) which were disconcordant with Vit-
rosTnI results (all VitrosTnI results  < 30 ng/L) (Group 1). In 
another five patients (Group 2) both results were elevated 
but the hsTnI results (range 216–15,659 ng/L) were 2–10 
times greater than the VitrosTnI results (range 96–1490 
ng/L) which is unexpected given that the VitrosTnI is posi-
tively biased against the Architect assay.
Re-analysis, dilutions and heterophile 
blocking
Re-centrifugation and re-analysis demonstrated that two 
of the discordant hsTnI results were due to random error in 
the Architect assay. Dilutions produced linear results in all 
cases. Incubation in Scantibodies tubes found no cases of 
heterophile antibody interference (recovery 85%–122%).
PEG precipitation
Recovery of hsTnI following PEG precipitation of 37 control 
samples (hsTnI range 6–815 ng/L) was 33%–61%. Recov-
ery following PEG precipitation of Group 1 samples was 
1%–15% (88% were   ≤  10% of original results) (p < 0.001). 
Post-PEG recovery from Group 2 samples was similar 
(1%–19% of original values) (p < 0.001) which is consistent 
with the presence of immunoglobulin-bound troponin  I. 
However, post-PEG recovery from two Group 2 samples 
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which had further elevation of hsTnI and VitrosTnI on 
serial testing was 21 and 29%.
Protein A/G/L
Recovery of hsTnI following Protein A/G/L treatment of 12 
control samples (pre-treatment hsTnI range: 49–815 ng/L) 
was 40%–70%. Recovery of IgG, IgA and IgM was  < 4%, 
11%–22% and 11%–18%, respectively (n = 6).
Recovery of 35 Group 1 samples was 2%–30% ( < 15% 
in 28 samples) (p < 0.001). Samples from three Group 
2 patients (hsTnI = 15,659, 608 and 213 ng/L vs. Vit-
rosTnI = 1490, 127 and 96 ng/L, respectively) were treated 
with Protein A/G/L and recoveries were 6%, 7% and 
37%, respectively (p < 0.01), consistent with the presence 
of immunoglobulin-bound troponin I. Carryover was not 
demonstrated at the concentrations in these samples 
except following the 15,659 ng/L specimen, after which 
carryover was observed to be 10 ng/L (0.06%).
Architect STAT Troponin-I
Plasma from 37 individuals with discordant troponin I 
results was analysed using the contemporary Architect 
STAT Troponin-I assay. Five results (18–26 ng/L) were 
below the manufacturer’s 99th percentile cut-off and cor-
responded with hsTnI levels of 19–31 ng/L. The remaining 
32 results ranged from 31–6320 ng/L corresponding with 
hsTnI concentrations 21–15,659 ng/L.
Gel filtration chromatography
Using the 9/300 column the peak elution volume of hsTnI 
was 4.0–5.0 mL in control (post-ST elevation MI) plasma 
(n = 4), and 2.3–3.3 mL in Group 1 specimens (n = 15). HsTnI 
in control plasma eluted before prolactin (23 kDa) and is 
presumed to be the 39 kDa binary troponin I-C complex (2). 
HsTnI in three specimens from Group 2, including the 
patient with 37% recovery following Protein A/G/L treat-
ment, eluted at both 4.0–5.0  mL (troponin I-C) and 2.3–
3.3 mL. Using the 10/400 column the peak elution volume 
of hsTnI was 10.6–11.9 mL in control plasma (n = 3) and 6.6–
7.6 mL in Group 1 patients (n = 7, including two previously 
analysed on the 9/300 column). Peak elution volumes for 
IgG, IgA and IgM using the 9/300 column were 3.6–4.0 
mL, 3.0–3.3 mL, and 1.0–1.3 mL, respectively (n = 9). Peak 
elution volumes for prolactin, IgG, IgA and IgM using the 
10/400 column were 12.5–12.9 mL, 9.2–9.6 mL, 7.9–8.3 mL, 
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Figure 1: Elution volumes vs. molecular weights in post-MI plasma 
of the troponin I-C complex and internal molecular weight markers 
using a 14 mL Sephacryl S-300 HR 9/300 GFC column and a 24 mL 
Sephacryl S-300 HR 10/400 GFC column.
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Figure 2: Elution profiles from the 10/400 column of 2 individuals, 
each with either troponin I-C (post-MI) or macrotroponin I.
The immunoglobulin and prolactin profiles are representative of the 
elution profiles from this column.
and 5 mL, respectively (n = 2). Figure 1 shows the  molecular 
weights against elution volumes for both columns.
Figure  2 displays elution profiles from the 10/400 
column of two  individuals with either MI (troponin I-C) 
or macroTnI. macroTnI elutes between the IgM and IgA 
peaks and the troponin I-C complex elutes between the 
IgG and prolactin peaks.
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EDTA plasma and serum
There was no difference in post-PEG recovery for EDTA 
plasma and serum specimens paired with lithium heparin 
plasma samples from patients with discordant cTnI results 
(n = 3).
Serial testing
Twenty-seven percent of patients with macroTnI had 
hsTnI elevation on serial testing. GFC was performed on 
plasma from two such patients and demonstrated a rise 
in both the macroTnI fraction and troponin I-C complex 
(Figure 3).
Serial testing after MI or cardiac surgery (n = 13) 
showed that, compared with VitrosTnI results, hsTnI in 
patients with macrotroponin rose disproportionately 
higher than expected, after taking the positive bias asso-
ciated with the VitrosTnI assay into account. Figure  4 
demonstrates this in four patients, one of which, (C), 
had hsTnI which persisted at very high levels for days 
after the VitrosTnI result had fallen and the patient was 
improving by all other parameters post-MI. HsTnI for 
patient (D) was high on admission with MI, fell in par-
allel with the VitrosTnI results but remains chronically 
elevated at 48 ng/L (post-PEG recovery = 2%) 3  months 
after admission.
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Figure 3: Elution profile (10/400 column) of hsTnI from a patient 
pre- and post-coronary artery bypass grafting (CABG) showing 
macrotroponin I in the pre-CABG specimen and macrotroponin I with 
troponin I-C complex post-CABG.
Sample mixing
Plasma from a patient with elevated troponin I-C post-MI 
was mixed (equal volumes incubated at room temperature 
for 10 min) with plasma from a patient with macroTnI. 
GFC of 1) 200 μL post-MI plasma, 2) 200 μL macroTnI 
plasma and 3) 400 μL mixed post-MI and macroTnI dem-
onstrated an elevation in the macroTnI peak with lower-
ing of the troponin I-C complex peak in the mixed sample 
(Figure 5).
Subsequent cases and clinical information
At the time of writing 102 cases (53 female) of macroTnI 
have been detected since the first case in March 2015. These 
are defined as having hsTnI above the sex-specific cut-
off, discordant with the VitrosTnI result, reproducible on 
repeat analysis and recovery post-PEG precipitation   ≤  15% 
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Figure 4: Time course of hsTnI vs. VitrosTnI results for patients 
with macrotroponin I (A) and (B) post-cardiac surgery, (C) and (D) 
post-MI.
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Figure 5: 10/400 column GFC of (1) post-MI plasma containing 
troponin I-C complex, (2) plasma from a patient with macrotroponin I 
and no myocardial injury and (3) a mixture of plasma from (1) and (2).
0
2
4
6
8
10
20 30 40 50 60 70 80 90 10
0
Fr
eq
ue
nc
y
Age, years
Females Males
MalesFemales
0
2
4
6
8
10
20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 10
0
M
or
e
Fr
eq
ue
nc
y
Age, years
0
5
10
15
20
25
30
35
50 10
0
15
0
20
0
25
0
30
0
35
0
40
0
45
0
50
0
55
0
60
0
65
0
70
0
M
or
e
Fr
eq
ue
nc
y
hsTnI, ng/L
C D
BA
0
5
10
15
20
50 10
0
15
0
20
0
25
0
30
0
35
0
40
0
45
0
50
0
55
0
60
0
65
0
70
0
M
or
e
Fr
eq
ue
nc
y
hsTnI, ng/L
Figure 6: Age distribution of macrotroponin I in (A) 53 females and (B) 49 males. Range of hsTnI values in (C) 53 females and (D) 49 males 
with macrotroponin I.
of the original result. Figure 6 shows the age distribution 
and hsTnI values for males and females.
According to clinical information from pathol-
ogy request forms or discussion with clinicians 65% of 
patients (aged 16–91 years) had presented to the emer-
gency department with chest or abdominal pain, dizzi-
ness, collapse or dyspnoea. Of these, 40% had histories 
of ischaemic heart disease, congestive cardiac failure or 
cardiomyopathy. Most of the others had risk factors for 
coronary artery disease such as hypertension, dyslipidae-
mia or diabetes mellitus. Ten patients had hsTnI requested 
either before or after an elective cardiac procedure. Eight 
patients (aged 14–87 years) had hsTnI measured follow-
ing emergency or elective surgical procedures, either as 
a routine or for the investigation of possible periopera-
tive myocardial damage. HsTnI was requested by general 
medical practitioners in the community for the investiga-
tion of chest pain in three patients. Three patients had 
hsTnI measured in the context of cardiotoxic chemother-
apy for malignancy. Four patients, with known heart or 
lung disease, had hsTnI measured before elective surgery. 
One patient was pregnant with chest pain and no history 
of heart disease.
Discussion
Five percent of elevated hsTnI results in this laboratory 
appear to be due to circulating macrotroponin, as evi-
denced by precipitation with PEG clearly below that of 
controls, depletion by Protein A/G/L, lack of evidence of 
the presence of heterophile antibodies and elution profile 
on GFC. Most of these are low level elevations ( < 100 ng/L) 
but have the potential to be clinically misleading. While 
this has become apparent with the adoption of the Archi-
tect High Sensitive Troponin-I assay, it is possible that the 
contemporary Architect STAT Troponin-I assay was simi-
larly affected given the majority of Group 1 samples were 
also above the 99th percentile for that assay. It is likely 
that the slightly increased rate of troponin I elevation with 
Brought to you by | University of Queensland - UQ Library
Authenticated
Download Date | 11/14/16 1:49 AM
Warner and Marshall: High incidence of macrotroponin I      1827
the improved sensitivity of the new assay in combination 
with a change in units by our laboratory from μg/L to ng/L, 
giving the impression of “higher numbers”, precipitated 
the clinicians’ enquiries which led to this investigation.
The GFC and PEG precipitation demonstrate that 
these elevated hsTnI results are due to high molecular 
weight complexes of troponin I. The Protein A/G/L data 
provide evidence that the complexes include immuno-
globulins as IgG, IgA and IgM were shown to be depleted 
by Protein A/G/L treatment and, according to the product 
information, Protein A/G/L binds the Fc fragment of IgG 
and kappa light chains, thereby depleting IgG, IgA, IgM, 
IgD and IgE immunoglobulins [35]). macroTnI elutes from 
the GFC column between molecular weights 340 and 
900  kDa indicating that the immunoglobulins involved 
could be IgG or IgA. The mixing studies and data from 
serial samples post-myocardial injury suggest that the 
complexes contain the troponin I-C complex but they 
could contain free troponin I or fragments of it. Further 
investigation is required to clarify this.
The mixing study and serial samples post-myocardial 
injury also suggest that circulating troponin I autoanti-
bodies scavenge free troponin I-C complex so that in vivo 
it rises higher and is cleared more slowly from the circula-
tion. The observation that autoantibody-positive patients 
have higher troponin I levels that persist longer post-MI 
has been reported [36]. Our data from serial measurements 
also suggest that antibody affinity and concentration 
vary from patient to patient as, compared with VitrosTnI 
results, the duration and degree of hsTnI elevation varies 
considerably.
As the risk of misdiagnosis and patient mismanage-
ment was high we thought that pre-emptive identification 
of macroTnI, in as close to ‘real time’ as possible, was 
warranted. Results from evaluation of the first 50 cases 
demonstrated that re-analysis and PEG precipitation were 
sufficient to clarify whether a discordant elevated hsTnI 
result was due either to random error or to high molecu-
lar weight interference. PEG precipitation does not dis-
tinguish between heterophile antibody interference and 
macroTnI but this can be clarified by GFC or treatment 
with heterophilic blocking reagents. Protein A/G/L treat-
ment confirmed PEG precipitation results and is specific 
for immunoglobulin-bound troponin but was a slower, 
more laborious process, a more expensive reagent and 
is not practical for rapid detection of macroTnI. GFC 
however, once set up, was easy to use and valuable in 
interpreting PEG precipitation results above 15% in Group 
2 patients.
While it is not feasible for many laboratories to rou-
tinely perform two troponin assays in parallel a suitable 
compromise may be to reanalyse and PEG precipitate 
specimens when serial troponin results do not change or 
results are not consistent with clinical and other findings. 
Differences in numerical results and concordance are 
expected between troponin I assays on individual samples 
for a variety of reasons and using a second assay to “vali-
date” the results of another does have limitations. While 
our approach was simple (investigate positive hsTnI, 
negative VitrosTnI) we consider it a pragmatic one that 
functioned well as a real time process in a routine clini-
cal laboratory. Our goal was to intercept and investigate 
possible false-positive hsTnI results as expeditiously as 
possible, given that the hsTnI assay is used routinely in 
our laboratory. As such, samples with a high VitrosTnI but 
normal hsTnI, which were comparatively infrequent, were 
not given the same level of scrutiny and are not presented 
here. In the long term, as other high-sensitivity troponin I 
assays are released onto the market, as long as they are 
shown not to detect macrotroponin, the combination of 
rapid diagnosis of MI with low risk of false positive results 
may be found in one assay.
Australia’s 99th percentile for the hsTnI assay is lower 
than is used elsewhere for males (26 vs. 34 ng/L) and eight 
(16%) of the male macroTnI patients had hsTnI values 
between 26 and 34 ng/L. Therefore laboratories using 
the manufacturer’s male-specific hsTnI cut-off will report 
fewer elevated results due to macroTnI.
Detection of macroTnI by the Architect hsTnI assay 
could be advantageous if, for example, evidence accumu-
lates that macroTnI has clinical significance (unproven) 
or contributes to the assay’s ability to precisely measure 
low levels of troponin (speculative). The corollary is that 
the VitrosTnI may be a disadvantage for not detecting this 
form of troponin, however, our study was not designed 
to answer this question. If the incidence of macroTnI in 
the general population is comparable to our findings, 
this would affect the current 99th percentile cut-off, as 
approximately 5% of control subjects would have some, 
albeit moderate elevation in cardiac troponin measured 
by hsTnI due to the presence of macroTnI. This would 
need to be confirmed, however, as macrotroponin may, for 
example, be more common after cardiac injury, so many of 
these individuals would be excluded from reference inter-
val studies.
True cTnI elevation and the presence of macroTnI 
are not mutually exclusive. Their co-existence can result 
in equivocal ( > 15% recovery) PEG precipitation results 
requiring further investigation (GFC or alternate troponin 
method) to clarify, as we saw in Group 2 patients who 
had both macroTnI and true elevation of cTnI second-
ary to acute myocardial damage. It is reassuring that the 
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presence of macroTnI does not appear to mask a true cTnI 
elevation due to myocardial injury, but may exaggerate it.
In the hsTnI assay the capture antibody is directed 
toward amino acid residues 24–40 while the detection 
antibody targets amino acids 41–54 [37]. The VitrosTnI 
assay has two capture antibodies targeting amino acid 
residues 24–40, and 41–49 with the detection antibody 
binding to residues 87–91. We present evidence that 
the Architect assay either captures or detects macroTnI 
complexes that the Ortho assay does not. Whether this 
is because of steric hindrance (perhaps of the detection 
antibody) by the autoantibody in the Ortho assay or due 
to displacement of the autoantibody from the troponin I 
molecule by reagent antibodies or other components 
in the Abbott assay requires investigation. It is possible 
that the Ortho assay also over-reports TnI concentrations 
because of macrotroponin, but to a lesser extent. Given 
the similar antibody configuration of most assays (2), it is 
likely that that other assays, possibly also for troponin T, 
measure macrotroponin. Perhaps circulating macrotro-
ponin should be added to the list of causes of persistent 
troponin elevation. A high index of suspicion and close 
liaison between clinicians and the laboratory are required 
to fully investigate the extent of this issue and determine 
a strategy for managing elevated troponin results due to 
macrotroponin.
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